Endometroid Adenocarcinoma: Unmet Needs and Future Directions in Care


Closing out his review of treatment options in the setting of recurrent endometroid adenocarcinoma, Matthew A. Powell, MD, highlights unmet needs and future directions in care.

Matthew A. Powell, MD
: When we look to the future, what do we have to look forward to with endometrial cancer? Honestly, this last year we’ve had more endometrial cancer trials than ever in history. There were 5 large, randomized trials going on at the same time looking at the addition of checkpoint inhibition to chemotherapy. Now we’ve seen 3 of the trials reports and show this positive signal in that area. We look to see whether the combination of lenvatinib and pembrolizumab may be moving to upfront therapy with the LEAP-001 trial [NCT03884101], which is upcoming, but we still have a lot of unmet needs. Some of that area has to deal with the disparity within outcomes for especially our Black and African American patients. We still don’t understand all the factors involved there. We know that there’s much increased risk of a higher-grade cancer in that population and we’re looking for areas to narrow this disparity that we’re seeing. Further targeted therapies will be helpful. One of the things that we see developing is a lot more antibody-drug conjugates that are targeting HER2, which is common in our high-grade cancers. So about 20% to 30% of our high-grade serous and … sarcomas are expected to have overexpression of the HER2 gene. We can target that with novel compounds. We’re also looking at other targets with antibody-drug conjugates and there are exciting areas. Looking at DNA repair and DNA damage repair, a whole other area within some of these high-grade cancers that, much like ovarian cancer, we hope to potentially be using PARP inhibitors for this population once we figure out what is the right biomarker for which patients should be treated. I think the time is exciting. There’s a lot of interest now for studying endometrial cancer. Unfortunately, with this increased risk and increased rate of endometrial cancer, a lot more needs to be done.

Transcript edited for clarity.

Related Videos
Video 8 - "Clinical Pearls for Optimal Management of mHSPC"
Video 7 - "Multidisciplinary Approach in mHSPC Management "
Video 6 - "Treatment Considerations in High Disease Burden and Comorbidities"
Video 5 - "Pivotal Trials in mHSPC"
Video 4 - "ARASENS Trial- Darolutamide in mHSPC"
Video 3 - "Treatment Intensification in Metastatic Prostate Cancer"
Video 2 - "Treatment Options for mHSPC"
Video 1 - "Initial Impression and Risk Assessment"
Yi-Bin Chen, MD, an expert on GVHD
Yi-Bin Chen, MD, an expert on GVHD
Related Content